CSPC Pharmaceutical Group Limited, The business manufactures NBP soft capsules and injections for people who have had a stroke and have memory and mental problems. An investment holding company, makes, researches, and sells pharmaceutical products in the People's Republic of China and other Asian countries, the United States, Europe, and around the world. It sells completed drugs, bulk products, functional foods, and other things.
The pills and inoculations are for patients with mild memory and mental problems. The drug Duomeisu is used to treat lymphoma, multiple myeloma, ovarian and mammary tumours as well as other malignant tumours. Enix is used to treat adult Parkinson's disease, while Jinyouli is used to prevent leukaemia and infections caused by chemotherapy. This medicine can also help with upper respiratory tract infections, diabetes, osteoporosis in postmenopausal women, CSPC also makes functional food and glucose products, and it researches and develops other products that help with oncology, immunology, psychiatry, neurology, digestion and metabolism, cardio-cerebrovascular system, and anti-infection. Further, it provides health care and sells pharmaceutical devices. The company used to be called China Pharmaceutical Group Limited. It was renamed to CSPC Pharmaceutical Group Limited in March of that year. CSPC Pharmaceutical Group Limited is headquartered in Shijiazhuang, which is in the People's Republic of China.
Full Time Employees: 21,527.
Stock price At close: January 12 04:00 PM HKT 9.240-0.010 (-0.11%).
Market cap 110.42B HKD.
CSPC Pharmaceutical Group Ltd (1093)
Get CSPC Pharmaceutical Group Ltd (1093) share price insights to guide your investment strategy. Stay updated with FP Markets Oman.